Identiv Leads The Charge In These 3 Promising Penny Stocks
This article highlights three promising penny stocks: Identiv (INVE), SIGA Technologies (SIGA), and Emergent BioSolutions (EBS), based on their financial health and market potential. While each company faces unique challenges like unprofitability or declining revenue, they also demonstrate strengths such as strong cash positions, no debt, or significant contracts. The analysis emphasizes that penny stocks can offer growth opportunities for investors despite their inherent risks.
SIGA Technologies Inc (SIGA) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for SIGA Technologies Inc (SIGA), detailing estimated future EPS, revenue, net
SIGA Technologies (SIGA) Stock Slips As Contract Uncertainty Trumps Profit
SIGA Technologies (SIGA) reported a profit in Q2 2026, but its stock still slipped due to contract uncertainty and declining revenue and EPS compared to the previous year. Despite a strong cash balance and no debt, the market is concerned about the volatility of TPOXX sales, which depend on a small group of government buyers with unpredictable procurement cycles. This has led to a significant drop in the stock over the past three months.
Siga Technologies Q2 Earnings Call Highlights
Siga Technologies reported $38 million in Q2 product revenue, driven by TPOXX sales to the U.S. Strategic National Stockpile and international customers, resulting in a net income of $12 million. The company is in ongoing discussions for a new multiyear TPOXX procurement agreement with the U.S. government, despite delays due to leadership changes within HHS. SIGA is also prioritizing international expansion and pipeline development, including a potential FDA submission for TPOXX in early 2027.
SIGA TECHNOLOGIES INC 2Q 2026: Revenue $41M, EPS $0.17— 10-Q Summary
SIGA TECHNOLOGIES INC reported its Q2 2026 results with revenue of $41 million and diluted earnings per share of $0.17, both significantly down from the prior-year quarter due to shifts in product mix and lower U.S. oral TPOXX® deliveries. The company's business remains heavily reliant on U.S. government procurements, though international sales showed an increase. Regulatory updates included the removal of the mpox indication for its product in Europe while retaining approvals for other conditions.
SIGA Technologies Inc (SIGA) (Q2 2026) Earnings Call Highlights: Strong Revenue and Strategic ...
SIGA Technologies Inc (SIGA) reported strong Q2 2026 product-related revenues of $38 million, driven by US Strategic National Stockpile deliveries and international sales. The company is diversifying its customer base and has a strong balance sheet with $118 million in cash and no debt. Despite these positives, SIGA faces delays in securing a new multi-year contract with the US government and uncertainty regarding future TPOXX deliveries and international procurement decisions.
SIGA Technologies Inc (SIGA) (Q2 2026) Earnings Call Highlights: Strong Revenue and Strategic ...
SIGA Technologies Inc. reported strong Q2 2026 product-related revenues of $38 million, driven by US Strategic National Stockpile deliveries and international sales. The company fulfilled its 19C contract obligations, diversified its customer base, and maintains a strong balance sheet with $118 million in cash. Despite these positives, delays in securing a new US government contract and the inherent variability of its business model pose challenges, though SIGA remains confident in its TPOXX role and is expanding international markets.
SIGA Q2 2026 Earnings: Lower TPOXX Sales Compress Revenue and Margins
SIGA Technologies reported a significant decline in Q2 2026 revenue and EPS due to lower TPOXX product sales and an unfavorable product mix, which compressed margins. The company delivered TPOXX to both U.S. and international customers, but the completion of a key U.S. procurement order and the nascent international market create uncertainty for future revenue. While remaining profitable, SIGA faces challenges related to securing new U.S. contracts, developing international demand, and managing product mix effects on profitability.
SIGA: Q2 2026 delivered $38M in revenues, $12M net income, and expanded global TPOXX reach
SIGA Technologies Inc. reported $38 million in product revenues for Q2 2026, primarily from U.S. and international TPOXX deliveries, alongside a net income of $12 million and robust cash reserves. The company is advancing new U.S. contracts and international expansion efforts, despite encountering slower government procurement cycles. This information is based on an AI-generated summary of SIGA's Q2 2026 audio transcript from August 6, 2026.
SIGA Technologies (NASDAQ: SIGA) Q2 income drops to $12.5M
SIGA Technologies reported a significant drop in Q2 2026 revenue to $41.0 million, down from $81.1 million a year prior, primarily due to decreased U.S. government purchases of oral TPOXX. Net income consequently fell to $12.5 million from $35.5 million. Despite the revenue decline, the company noted a shift towards IV TPOXX and new international orders, and highlighted its substantial BARDA contract capacity and healthy cash reserves of $117.6 million.
SIGA Technologies (SIGA) Stock Rises on Q2 2026 Earnings
This article announces that SIGA Technologies (SIGA) stock has risen following its Q2 2026 earnings report. No further details about the earnings or the stock performance are provided.
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026
SIGA Technologies, Inc. announced its financial results for the three and six months ended June 30, 2026, reporting approximately $37 million in TPOXX sales for the second quarter. This included $24 million of IV TPOXX to the U.S. strategic national stockpile and $13 million of oral TPOXX to international customers, completing deliveries under the 19C contract. The company also declared a special cash dividend of $0.60 per share in March 2026.
Arrowstreet Capital Limited Partnership Has $8.16 Million Stock Holdings in Siga Technologies Inc. $SIGA
Arrowstreet Capital Limited Partnership significantly increased its stake in Siga Technologies Inc. by 48.9% in the first quarter, now holding 1.53 million shares valued at $8.16 million. Despite this increased institutional interest, analysts have issued a "Sell" rating for SIGA, with shares opening at $3.27, close to its one-year low. The company specializes in medical countermeasures and is known for its smallpox antiviral, TPOXX®.
SIGA Technologies (SIGA.US) will release its earnings report after market close on August 6.
SIGA Technologies (SIGA.US) is scheduled to release its earnings report on August 6, after the market closes. This announcement informs investors and stakeholders about the upcoming financial disclosure for the company.
SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
SIGA Technologies Inc. announced that it will host a webcast and conference call on August 6, 2026, at 4:30 P.M. ET to provide a business update following the release of its second-quarter 2026 financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire, with a live webcast available on the company's website. SIGA is a commercial-stage pharmaceutical company focused on developing medicines to treat and prevent infectious diseases, particularly orthopoxviruses.
SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
SIGA Technologies Inc. announced that it will host a webcast and conference call on August 6, 2026, at 4:30 P.M. ET to provide a business update following the release of its second-quarter 2026 financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. SIGA is a commercial-stage pharmaceutical company focused on developing innovative medicines to treat and prevent infectious diseases, particularly orthopoxviruses.
SIGA CEO and CFO Join Aug. 6 Business Update Webcast
SIGA Technologies, Inc. (Nasdaq: SIGA) announced that its CEO Diem Nguyen and CFO Daniel Luckshire will host a webcast and conference call on Thursday, August 6, 2026, at 4:30 P.M. ET. The call will provide a business update following the release of the company's second-quarter 2026 financial results. Investors can access the live webcast or a replay via the company's website or dedicated dial-in numbers.
SIGA Technologies Inc (SIGA) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for SIGA Technologies Inc (SIGA), detailing its volatility, financial risk, and investment risk. It notes that SIGA has a risk assessment score of 5.23, ranking 71st in the Pharmaceuticals industry, and a beta of 0.92, indicating it tends to underperform in up markets but decline less in down markets. The report also includes specific metrics like VaR, maximum drawdown, volatility, return statistics, Sharpe Ratio, and liquidity indicators.
SIGA Technologies Inc (SIGA) Institutional Confidence
The article analyzes the institutional confidence score for SIGA Technologies Inc (SIGA), which stands at 5.00, placing it 72nd in the Pharmaceuticals industry. Institutional shareholding proportion increased by 10.57% quarter-over-quarter, with HOTCHKIS & WILEY as the largest institutional shareholder despite a slight decrease in their holdings. The report also lists top institutional shareholders and their recent activity.
SIGA Technologies Inc Today's Market Trends | SIGA Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey
This article provides an in-depth analysis of SIGA Technologies Inc. (SIGA) stock, including real-time quotes, market trends, key financials, and trading strategies. It highlights the company's strong fundamentals and growth potential, despite recent stock market performance, and details its flagship product, TPOXX, an antiviral medicine for orthopoxviruses. The report also includes technical indicators, shareholder information, and industry comparisons.
SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
SIGA Technologies, Inc. (Nasdaq: SIGA) announced it will host a webcast and conference call on August 6, 2026, at 4:
SIGA Technologies Inc (SIGA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of SIGA Technologies Inc (SIGA), highlighting its current valuation score and financial ratios. The company's valuation score is 5.26, ranking low within the Pharmaceuticals industry. It also details SIGA's current P/E ratio, noting its position relative to recent highs and lows.
SIGA Technologies Inc Financials
This article provides a detailed financial overview of SIGA Technologies Inc. It presents the company's financial summary, including income statement, balance sheet, and cash flow statement data, both quarterly and annually. Key financial indicators like EPS, revenue, net profit, net margin, and gross margin are highlighted, along with future earnings dates and historical performance.
SIGA Technologies Inc (SIGA) Cash Flow
This article provides a detailed cash flow statement for SIGA Technologies Inc (SIGA), outlining quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as operating cash flow, net income from continuing operations, capital expenditures, and free cash flow. The article also includes a FAQ section defining these financial terms and their significance for investors.
SIGA Technologies Inc (SIGA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for SIGA Technologies Inc (SIGA), focusing on its regional revenue contributions. As of the latest update, relevant data for future fiscal years and business segments has not yet been disclosed by the company. The current disclosed regional revenue shows the United States as the primary contributor, followed by Canada.
SIGA Technologies Inc (SIGA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of SIGA Technologies Inc (SIGA), listing its major individual and institutional holders, and categorizing shareholders by type. It also provides a historical overview of institutional shareholding data and recent shareholder activity, along with ETFs that hold SIGA shares. The data indicates MacAndrews & Forbes Holdings, Inc. as the largest shareholder.
SIGA Technologies Inc (SIGA) - Stock Score & Comprehensive Stock Analysis
This article provides a comprehensive stock analysis of SIGA Technologies Inc (SIGA) based on TradingKey's stock score, highlighting its relatively healthy fundamentals and high growth potential, despite a recent weak stock market performance. The company's valuation is considered fairly valued in the Pharmaceuticals industry, with very high institutional ownership. SIGA's flagship product, TPOXX, an antiviral medicine for infectious diseases like smallpox and monkeypox, is also detailed.
SIGA Technologies (SIGA) Q2 2025 earnings summary
SIGA Technologies reported significant financial growth in Q2 2025, with revenues reaching $81.1 million and net income increasing to $35.5 million due to strong government sales of TPOXX. The company secured additional BARDA funding and paid a special cash dividend. However, future international sales might be affected by an EMA referral procedure concerning Tecovirimat-SIGA's effectiveness against mpox.
3 Promising Stocks Estimated To Be Up To 26.7% Below Intrinsic Value
The article highlights three U.S. stocks—SIGA Technologies (SIGA), Extreme Networks (EXTR), and Ramaco Resources (METC)—that are estimated to be significantly undervalued based on discounted cash flow analysis. These companies are projected to experience strong earnings and revenue growth, suggesting potential opportunities for investors despite various market conditions and strategic challenges like potential shareholder dilution for METC.
3 Promising Stocks Estimated To Be Up To 26.7% Below Intrinsic Value
This article highlights three US stocks—SIGA Technologies (SIGA), Extreme Networks (EXTR), and Ramaco Resources (METC)—that are estimated to be trading below their intrinsic value based on discounted cash flow analysis. Despite a flat US market, these companies show strong growth forecasts with potential for significant earnings increases, offering attractive investment opportunities. The analysis includes their market caps, primary revenue sources, and estimated discounts to fair value.
SIGA Technologies highlights its antiviral niche as investors track Nasdaq biotech sentiment
SIGA Technologies specializes in antiviral treatments, particularly those linked to biosecurity and infectious-disease risks, distinguishing itself within the Nasdaq biotech sector. The company's business model heavily relies on long-term government contracts and preparedness programs, which provide a unique revenue stream less susceptible to typical consumer demand cycles. Investors track SIGA's performance by considering its ability to secure government procurement decisions and its role in national and international emergency response plans, alongside broader biotech market sentiment.
Price to earnings forward of SIGA Technologies Inc. – NASDAQ:SIGA
This article provides financial information for SIGA Technologies Inc. (NASDAQ: SIGA), specifically focusing on its forward price-to-earnings ratio. It is presented in the context of TradingView's platform, offering tools and data for market analysis. The content is primarily a listing of navigation options and disclaimers for the TradingView website.
Enterprise value to EBITDA forward of SIGA Technologies Inc. – NASDAQ:SIGA
This page from TradingView displays the Enterprise Value to forward EBITDA for SIGA Technologies Inc. (NASDAQ: SIGA). It indicates that the market was closed with no trades. The content is primarily a financial data point for the company, accessible through TradingView's platform.
Is SIGA Technologies’ (SIGA) Index Shift and ESOP Shelf Raising a New Value-Defensive Story?
SIGA Technologies (SIGA) was reclassified in June 2026, moving from Russell growth benchmarks to the Russell 2000 Defensive and Value-Defensive indices. This shift, alongside a US$28.08 million ESOP-related shelf registration, redefines the company's investment narrative from a pure growth play to a more defensive, cash-generative stock. While core catalysts remain unchanged, the reclassification highlights existing risks concerning earnings volatility and capital allocation.
Price to sales forward of SIGA Technologies Inc. – NASDAQ:SIGA
This article focuses on the "Price to sales forward" metric for SIGA Technologies Inc. (NASDAQ: SIGA). It provides a high-level overview of this financial ratio for the company, accessible through TradingView. The content appears to be a financial data point without deeper analysis or commentary.
Enterprise value to revenue forward of SIGA Technologies Inc. – NASDAQ:SIGA
This article focuses on the enterprise value to revenue forward metric for SIGA Technologies Inc. (NASDAQ: SIGA). It provides a high-level overview of the company's financial data within the context of the pharmaceutical and health technology sectors. The content is primarily a listing of navigation and copyright information from the TradingView platform.
SIGA Technologies, Inc.(NasdaqGM: SIGA) dropped from Russell 2500 Growth Benchmark
SIGA Technologies, Inc. (NasdaqGM: SIGA) has been removed from the Russell 2500 Growth Benchmark, according to an S&P Capital IQ report published on June 29, 2026. This news follows several other index changes for the company, including being dropped from the Russell Small Cap Comp Growth Benchmark and Russell 2000 Growth Benchmark, while also being added to the Russell 2000 Value-Defensive Index. The company is a commercial-stage pharmaceutical firm specializing in infectious disease treatments, with its flagship product TPOXX approved for smallpox and other related viruses.
SIGA Technologies, Inc.(NasdaqGM: SIGA) dropped from Russell 2000 Growth Benchmark
SIGA Technologies, Inc. (NasdaqGM: SIGA) has been removed from the Russell 2000 Growth Benchmark and the Russell 3000E Growth Benchmark. This news follows a previous report that the company was added to the Russell 2000 Value-Defensive Index. The company is a commercial-stage pharmaceutical firm specializing in infectious diseases, with its primary product, TPOXX, an antiviral medicine for smallpox, monkeypox, and cowpox.
SIGA Technologies, Inc.(NasdaqGM: SIGA) added to Russell 2000 Value-Defensive Index
SIGA Technologies, Inc. (NasdaqGM: SIGA) has been included in the Russell 2000 Value-Defensive Index. The company is a commercial-stage pharmaceutical firm specializing in infectious disease treatments, with its flagship product TPOXX being an antiviral medicine for smallpox and monkeypox. The article also provides recent news on SIGA, including its earnings reports and dividend declarations.
SIGA Technologies: SIGA Technologies Inc. - Cash Distribution Option Symbol: SIGA
This article concerns SIGA Technologies, specifically announcing a cash distribution option related to the company's stock symbol SIGA. The content itself seems to be a placeholder, stating "Document."
SIGA Technologies Inc Actuals & Estimates (NASDAQ:SIGA)
This article provides an overview of SIGA Technologies Inc. (NASDAQ:SIGA) stock performance, financial data, and analyst estimates. It highlights recent stock price changes, future forecasts, historical highs and lows, and key financial metrics like net income and EBITDA. The content also includes information on the company's next earnings date and technical analysis signals.
SIGA Technologies Inc (SIGA) Financial Health: Profitability & Balance Sheet Analysis
SIGA Technologies Inc (SIGA) has a current financial score of 9.00, ranking 21st out of 157 in the Pharmaceuticals industry, indicating robust financial health and high operating efficiency. Despite this strong overall score, the company reported a year-over-year revenue decrease of 11.34% to $6.24 million and a significant net profit decrease of 746.17% in its latest quarter. The analysis highlights key financial metrics like cash and cash equivalents, total assets, and free cash flow as aspects where relevant data has not yet been disclosed by the company.
SIGA Technologies Inc (SIGA) Valuation: PE, PB & Fair Value Analysis
SIGA Technologies Inc (SIGA) currently holds a valuation score of 7.37, ranking 129th out of 157 companies in the Pharmaceuticals industry. Its P/E ratio stands at 15.27, which is a considerable increase from its recent low but still below its recent high. The article notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
SIGA Technologies Inc (SIGA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of SIGA Technologies Inc (SIGA), listing its major individual and institutional holders and their respective proportional ownership. It also provides a breakdown of shareholder types and a historical overview of institutional shareholding changes over several quarters.
SIGA Technologies Inc (SIGA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of SIGA Technologies Inc. (SIGA), focusing on its support and resistance levels, various technical indicators, and moving averages. The stock is currently trading between a resistance of $4.67 and a support of $4.07, suggesting a range-bound swing trading opportunity. Technical indicators like MACD and TRIX show sell signals, while most moving averages also indicate a sell signal, with a current price momentum score of 6.66.
SIGA Technologies Inc (SIGA) Institutional Confidence
The article analyzes the institutional confidence in SIGA Technologies Inc (SIGA), noting its current shareholding score of 5.00, ranking 73rd in the Pharmaceuticals industry. Institutional shareholding proportion increased by 10.57% quarter-over-quarter, with Hotchkis & Wiley being the largest institutional shareholder. The article also lists major institutional shareholders and their recent activity.
SIGA SEC Filings - Siga Technologie 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Siga Technologie (SIGA) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. Recent notable filings include a Form 4 detailing CEO Diem Nguyen's equity compensation activity in January 2026, and Q3 2025 results showing lower quarterly revenue but strong nine-month profit. The filings document the company's business focused on TPOXX and infectious-disease countermeasures, with updates on revenue, product deliveries, and R&D.
SIGA Technologies (SIGA) director exercises RSUs and disposes shares to issuer
SIGA Technologies director Harold Eugene Ford Jr. engaged in several equity transactions on June 9, 2026. He disposed of 7,235 common stock shares to the issuer at $4.39 each and exercised derivative awards to acquire 24,116 common stock shares at $0.00. Additionally, he received a new grant of 34,169 restricted stock units (RSUs) which will vest at the company's 2027 annual meeting, with a portion potentially settled in cash.
SIGA Technologies (SIGA) director exercises RSUs and returns 7,235 shares
SIGA Technologies director John M. Keane reported exercising 24,116 restricted stock units (RSUs) into common stock and returning 7,235 shares to the company at $4.39 per share. He also received a new grant of 34,169 RSUs, which will fully vest at the company's 2027 annual meeting. These transactions are considered routine director equity compensation and have a neutral impact on shareholders.
SIGA Technologies (SIGA) director reshapes holdings with RSU exercise
SIGA Technologies director Gary J. Nabel has adjusted his holdings through RSU transactions. He exercised 24,116 restricted stock units and then disposed of 7,235 common shares back to the company for $4.39 per share, leaving him with 80,989 direct shares. Additionally, Nabel received a new grant of 34,169 RSUs that will vest in 2027, with a portion potentially being cash-settled for tax purposes.
